2014 with EBITDA of 25.6 million euro (+17.7%) and net income of 17.5 million euro (+24.3%) .
Revenues increased by +7%, to 117 million euro, with growth in sales of Yondelis® (+8%) and in Consumer Chemicals (+8%).
Group EBITDA expanded by +17.7%, to 25.6 million euro, to which the oncology area contributed 29.1 million euro (+12%).
Total net debt has been cut by 11% since the beginning of the year.
Madrid, 30 October 2014: Zeltia Group (Grupo Zeltia, ZEL.MC) announces its financial and corporate results for the first 9 months of 2014. Zeltia's net sales amounted to 117 million euro in the first nine months of 2014, up 7% with respect to the same period last year. Sales expanded during the period in both Biopharmaceuticals, with 61.2 million euro (+7%), and Consumer Chemicals, with
57.4 million euro (+8%). Within the Biopharmaceutical area, Yondelis® sales
amounted to 57.4 million euro, i.e. an increase of 8% with respect to the same period last year.
Grupo Zeltia's EBITDA amounted to 25.6 million euro in the first nine months of
2014, an 18% increase year-on-year. The main contributor to EBITDA was the oncology business, with 29 million euro (25.9 million euro in 9M13).
EBITDA increased despite greater R&D spending on the various trials with compound PM1183 and on the Phase III registration trial with Aplidin® in multiple myeloma, for which recruitment is advancing at a good pace.
Grupo Zeltia's attributable net profit amounted to 17.5 million euro in 9M14, compared with 14.1 million euro in 9M13 (+24.3%).
The group's net interest-bearing debt improved by 11% with respect to the beginning of the year, and its cash position amounted to 37.3 million euro.